Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.15 -0.3%	$3.12	$2.01 ▼ $5.64	$209.57M	1.61	1.19 million shs	2.15 million shs
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$269.78M	3.05	142,780 shs	870,126 shs
IMMX Immix Biopharma	$2.17 -3.1%	$2.14	$1.26 ▼ $3.00	$60.50M	0.31	153,360 shs	170,910 shs
INZY Inozyme Pharma	$3.99 -0.3%	$2.91	$0.72 ▼ $6.24	$257.59M	2.27	915,180 shs	4.96 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	+1.61%	-5.69%	+0.32%	+41.89%
FHTX Foghorn Therapeutics	0.00%	+2.54%	+16.91%	+32.60%	-15.83%
IMMX Immix Biopharma	0.00%	-3.13%	-6.87%	+29.17%	+9.60%
INZY Inozyme Pharma	0.00%	0.00%	+1.01%	+338.46%	-10.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.6543 of 5 stars	3.4	1.0	2.7	0.0	0.6
FHTX Foghorn Therapeutics	2.1026 of 5 stars	3.6	0.0	3.2	1.7	0.6
IMMX Immix Biopharma	3.6132 of 5 stars	3.5	5.0	2.2	3.3	0.6
INZY Inozyme Pharma	3.5471 of 5 stars	4.2	4.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	213.49% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	222.58% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	194.49% Upside

Current Analyst Ratings Breakdown

Latest IMMX, INZY, CRDF, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	308.19	N/A	N/A	$1.86 per share	1.69
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)

Latest IMMX, INZY, CRDF, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
FHTX Foghorn Therapeutics	N/A	3.16	3.16
IMMX Immix Biopharma	N/A	1.80	1.80
INZY Inozyme Pharma	0.65	2.19	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FHTX Foghorn Therapeutics	61.55%
IMMX Immix Biopharma	11.26%
INZY Inozyme Pharma	88.30%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
FHTX Foghorn Therapeutics	7.58%
IMMX Immix Biopharma	55.40%
INZY Inozyme Pharma	12.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable

IMMX, INZY, CRDF, and FHTX Headlines

Recent News About These Companies

Inozyme Pharma Inc Ordinary Shares

June 21, 2025 | morningstar.comM

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025 | globenewswire.com

Inozyme Pharma Reports Increased Loss Amid Strategic Focus

June 9, 2025 | tipranks.com

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Hold" from Brokerages

June 9, 2025 | marketbeat.com

Millennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)

May 30, 2025 | marketbeat.com

BMRN to Acquire Inozyme Pharma

May 22, 2025 | finance.yahoo.com

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025 | businesswire.com

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A

May 18, 2025 | genengnews.comG

Jefferies Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Needham Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

May 17, 2025 | finance.yahoo.com

BioMarin to buy rare disease drugmaker Inozyme for $270M

May 16, 2025 | biopharmadive.comB

Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price

May 16, 2025 | marketwatch.com

BioMarin to Acquire Inozyme Pharma for $270M

May 16, 2025 | contractpharma.comC

BioMarin stock rises following Inozyme Pharma acquisition

May 16, 2025 | in.investing.com

BioMarin buys Inozyme for $270 million

May 16, 2025 | thepharmaletter.comT

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

May 16, 2025 | msn.com

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

May 16, 2025 | msn.com

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

May 16, 2025 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders

May 16, 2025 | prnewswire.com

INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders

May 16, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, INZY, CRDF, and FHTX Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.15 -0.01 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.35 +0.20 (+6.35%)

As of 04:00 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Immix Biopharma NASDAQ:IMMX

$2.17 -0.07 (-3.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.09 (-4.15%)

As of 04:00 AM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Inozyme Pharma NASDAQ:INZY

$3.99 -0.01 (-0.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.00 +0.01 (+0.25%)

As of 04:00 AM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time